OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical firm engaged within the discovery and improvement of novel immunotherapeutics and vaccines, right this moment introduced the promotion of Gemma Brown as Chief Financial Officer (CFO). Gemma Brown succeeds Georgy Egorov.
“Gemma has been highly engaged with all financial activities at Vaccitech including working with our auditors, corporate budgeting, SEC financial filings and other activities so we anticipate a seamless transition,” mentioned Bill Enright, Chief Executive Officer of Vaccitech. “I want to personally thank Georgy for his contributions to Vaccitech particularly his efforts that led to our successful IPO in 2021. We wish him the best in his future endeavors.”
Gemma Brown is an skilled monetary govt who joined Vaccitech as its Head of Financial Reporting in 2021, earlier than her promotion to CFO. In that position, she was accountable for almost all of the work associated to quarterly/annual monetary actions, compiling SEC filings, was a key contributor in different company finance actions and labored along with her now predecessor to develop the annual company funds. Prior to becoming a member of Vaccitech, Gemma was at EY the place she held positions of accelerating accountability, reaching the extent of Senior Manager and collaborating of their accelerated management applications. While at EY, she labored with shoppers throughout the U.S. and UK capital markets and was chargeable for servicing a number of rising biopharmaceutical firms who achieved listings on Nasdaq, both by way of an preliminary public providing or M&A transaction, and subsequent follow-on capital raises. She holds a B.Sc. in Biological Sciences and is a Chartered Accountant with the Institute of Chartered Accountants in England & Wales.
“I have spent most of my career assisting emerging biopharmaceutical companies and am passionate about positioning them financially for future success,” mentioned Gemma Brown, CFO.” I’m wanting ahead to increasing my monetary tasks at Vaccitech and dealing carefully with Bill and the administration workforce to proceed to develop the corporate. I additionally need to thank Georgy for his steering and help throughout our time working collectively.”
About Vaccitech plc
Vaccitech (“the Company”) is a clinical-stage biopharmaceutical firm engaged within the discovery and improvement primarily of novel immunotherapies for the remedy of power infectious ailments, most cancers, autoimmunity and ailments the place the T cell arm of the immune system is believed to play an vital position. The Company’s proprietary platforms embody modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), different viral vectors together with the well-validated Modified Vaccinia Ankara (MVA) and artificial nano-particle applied sciences (SNAPvax™ and Syntholytic™). The mixture of various applied sciences in a mixture and match strategy (heterologous prime-boost) persistently generates considerably greater magnitudes of T cells in contrast with different applied sciences and approaches. The Company has a broad pipeline of each medical and preclinical stage therapeutic applications to deal with strong tumors, power viral infections, as nicely as a couple of prophylactic viral vaccine applications. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now permitted to be used in lots of territories and solely licensed worldwide to AstraZeneca by way of Oxford University Innovation, or OUI. Vaccitech is entitled to obtain a share of all milestones and royalty revenue obtained by OUI from AstraZeneca.
Forward Looking Statement
This press launch comprises forward-looking statements, inside the which means of the Private Securities Litigation Reform Act of 1995, as amended, which might usually be recognized as such by use of the phrases “forward,” ”proceed,” and related expressions, though not all forward-looking statements include these figuring out phrases. These ahead wanting statements embody categorical or implied statements concerning the Company’s future expectations, plans and prospects, and embody, with out limitation, statements concerning the Company’s management transition. Any forward-looking statements on this press launch are primarily based on administration’s present expectations and beliefs and are topic to quite a few dangers, uncertainties and vital elements that will trigger precise occasions or outcomes to vary materially from these expressed or implied by any forward-looking statements contained on this press launch, together with, with out limitation, dangers and uncertainties associated to the management transition and different dangers recognized within the Company’s filings with the Securities and Exchange Commission (the “SEC”), together with its Annual Report on Form 10-Ok for the 12 months ended December 31, 2021, its Quarterly Report on Form 10-Q for the second quarter of 2022 and subsequent filings with the SEC. The Company cautions you to not place undue reliance on any forward-looking statements, which communicate solely as of the date they’re made. The Company expressly disclaims any obligation to publicly replace or revise any such statements to replicate any change in expectations or in occasions, circumstances or circumstances on which any such statements could also be primarily based, or that will have an effect on the chance that precise outcomes will differ from these set forth within the forward-looking statements.
Vaccitech IR contact
Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: [email protected]
Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc. (U.S.)
Email: [email protected] / [email protected]
